<DOC>
	<DOCNO>NCT02763969</DOCNO>
	<brief_summary>The purpose study establish BMS-986202 safe effective treat autoimmune disease psoriasis . BMS-986202 show promise preclinical study inhibit autoimmune condition psoriasis . This study first time drug give human .</brief_summary>
	<brief_title>Safety Study BMS-986202 Healthy Subjects Treat Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<mesh_term>Famotidine</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Healthy Male Female participant 18 50 year age ( Parts AD ) 18 70 year age ( Part E ) Diagnosed plaque psoriasis ( Part E ) Participants recent infection Participants Low Blood Pressure Participants heart relate problem Participants cancer Participants major medical illness Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>